Relay Therapeutics gets US FDA Breakthrough Therapy Designation for zovegalisib to treat advanced breast cancer: Cambridge, Massachusetts Thursday, February 5, 2026, 16:00 Hrs [IS ...

They also worried about Palantir’s ability to add new customers fast enough. “While revenue growth has been inflecting, the ...

Read the Sequoia Fund Q4 2025 letter for insights on Alphabet and AI growth. Explore our top ten holdings and investment strategy today.

To find the best ETFs to buy to participate in the small-cap stock revival, we screened for those ETFs earning a Morningstar ...

This week, it’s two-for-one in our stock screen section. Based on two stockpicking methods developed by the financial ...

A year's worth of our rigorous lab-testing scores plus your top brand recommendations come together to create our definitive ...

U.S. jobs data will come back into focus in the coming week as investors assess the likely timing of the next Federal Reserve ...

Kemper (NYSE:KMPR) executives struck a candid tone on the company’s fourth-quarter 2025 earnings call, with interim CEO Tom ...

Consequently, AMAT is now trading at a forward P/E of 34x, nearly double its 10-year median of approximately 18x, and is ...

Objective To compare the diagnostic accuracy of minipad collected menstrual blood versus clinician collected cervical samples to test for human papillomavirus (HPV) in the detection of cervical ...

In a year that surprised skeptics, China equities delivered strong performance in 2025, buoyed by improving corporate ...

Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of ...